These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 31406252)

  • 1. circKDM4C suppresses tumor progression and attenuates doxorubicin resistance by regulating miR-548p/PBLD axis in breast cancer.
    Liang Y; Song X; Li Y; Su P; Han D; Ma T; Guo R; Chen B; Zhao W; Sang Y; Zhang N; Li X; Zhang H; Liu Y; Duan Y; Wang L; Yang Q
    Oncogene; 2019 Oct; 38(42):6850-6866. PubMed ID: 31406252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correction: circKDM4C suppresses tumor progression and attenuates doxorubicin resistance by regulating miR-548p/PBLD axis in breast cancer.
    Liang Y; Song X; Li Y; Su P; Han D; Ma T; Guo R; Chen B; Zhao W; Sang Y; Zhang N; Li X; Zhang H; Liu Y; Duan Y; Wang L; Yang Q
    Oncogene; 2021 Apr; 40(15):2816. PubMed ID: 33767441
    [No Abstract]   [Full Text] [Related]  

  • 3. Long noncoding RNA MEG3 suppresses cell proliferation, migration and invasion, induces apoptosis and paclitaxel-resistance via miR-4513/PBLD axis in breast cancer cells.
    Zhu M; Wang F; Mi H; Li L; Wang J; Han M; Gu Y
    Cell Cycle; 2020 Dec; 19(23):3277-3288. PubMed ID: 33121324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. circKDM4C enhances bladder cancer invasion and metastasis through miR-200bc-3p/ZEB1 axis.
    Ma X; Ying Y; Sun J; Xie H; Li J; He L; Wang W; Chen S; Shen H; Yi J; Luo J; Wang X; Zheng X; Liu B; Xie L
    Cell Death Discov; 2021 Nov; 7(1):365. PubMed ID: 34811353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CircKDM4C upregulates P53 by sponging hsa-let-7b-5p to induce ferroptosis in acute myeloid leukemia.
    Dong LH; Huang JJ; Zu P; Liu J; Gao X; Du JW; Li YF
    Environ Toxicol; 2021 Jul; 36(7):1288-1302. PubMed ID: 33733556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aberrant KDM5B expression promotes aggressive breast cancer through MALAT1 overexpression and downregulation of hsa-miR-448.
    Bamodu OA; Huang WC; Lee WH; Wu A; Wang LS; Hsiao M; Yeh CT; Chao TY
    BMC Cancer; 2016 Feb; 16():160. PubMed ID: 26917489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Linc00518 Contributes to Multidrug Resistance Through Regulating the MiR-199a/MRP1 Axis in Breast Cancer.
    Chang L; Hu Z; Zhou Z; Zhang H
    Cell Physiol Biochem; 2018; 48(1):16-28. PubMed ID: 30001527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. miR-520b Inhibits IGF-1R to Increase Doxorubicin Sensitivity and Promote Cell Apoptosis in Breast Cancer.
    Zhang H; Zheng XD; Zeng XH; Li L; Zhou Q
    Yakugaku Zasshi; 2021 Mar; 141(3):415-426. PubMed ID: 33116033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated expression of circular RNA circ_0008450 predicts dismal prognosis in hepatocellular carcinoma and regulates cell proliferation, apoptosis, and invasion via sponging miR-548p.
    Zhang J; Chang Y; Xu L; Qin L
    J Cell Biochem; 2019 Jun; 120(6):9487-9494. PubMed ID: 30556306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circular RNA circ_0073181 contributes to tumorigenesis by regulating protein tyrosine phosphatase receptor type E via miR-548p in hepatocellular carcinoma.
    Wang Y; Wang H; Jia Y; Wang X; Yang C; Xue T
    Anticancer Drugs; 2022 Feb; 33(2):167-177. PubMed ID: 34657099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LncRNA NORAD accelerates the progression and doxorubicin resistance of neuroblastoma through up-regulating HDAC8 via sponging miR-144-3p.
    Wang B; Xu L; Zhang J; Cheng X; Xu Q; Wang J; Mao F
    Biomed Pharmacother; 2020 Sep; 129():110268. PubMed ID: 32563146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MiR-873/PD-L1 axis regulates the stemness of breast cancer cells.
    Gao L; Guo Q; Li X; Yang X; Ni H; Wang T; Zhao Q; Liu H; Xing Y; Xi T; Zheng L
    EBioMedicine; 2019 Mar; 41():395-407. PubMed ID: 30803931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MiR-770 suppresses the chemo-resistance and metastasis of triple negative breast cancer via direct targeting of STMN1.
    Li Y; Liang Y; Sang Y; Song X; Zhang H; Liu Y; Jiang L; Yang Q
    Cell Death Dis; 2018 Jan; 9(1):14. PubMed ID: 29323124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA-21 modulates chemosensitivity of breast cancer cells to doxorubicin by targeting PTEN.
    Wang ZX; Lu BB; Wang H; Cheng ZX; Yin YM
    Arch Med Res; 2011 May; 42(4):281-90. PubMed ID: 21820606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased expression of P-glycoprotein and doxorubicin chemoresistance of metastatic breast cancer is regulated by miR-298.
    Bao L; Hazari S; Mehra S; Kaushal D; Moroz K; Dash S
    Am J Pathol; 2012 Jun; 180(6):2490-503. PubMed ID: 22521303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Curcumol enhances the sensitivity of doxorubicin in triple-negative breast cancer via regulating the miR-181b-2-3p-ABCC3 axis.
    Zeng C; Fan D; Xu Y; Li X; Yuan J; Yang Q; Zhou X; Lu J; Zhang C; Han J; Gu J; Gao Y; Sun L; Wang S
    Biochem Pharmacol; 2020 Apr; 174():113795. PubMed ID: 31926937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-193b Modulates Resistance to Doxorubicin in Human Breast Cancer Cells by Downregulating MCL-1.
    Long J; Ji Z; Jiang K; Wang Z; Meng G
    Biomed Res Int; 2015; 2015():373574. PubMed ID: 26526790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-491-5p functions as a tumor suppressor by targeting JMJD2B in ERα-positive breast cancer.
    Hui Z; Yiling C; Wenting Y; XuQun H; ChuanYi Z; Hui L
    FEBS Lett; 2015 Mar; 589(7):812-21. PubMed ID: 25725194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-34a modulates chemosensitivity of breast cancer cells to adriamycin by targeting Notch1.
    Li XJ; Ji MH; Zhong SL; Zha QB; Xu JJ; Zhao JH; Tang JH
    Arch Med Res; 2012 Oct; 43(7):514-21. PubMed ID: 23085450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SPIN1, negatively regulated by miR-148/152, enhances Adriamycin resistance via upregulating drug metabolizing enzymes and transporter in breast cancer.
    Chen X; Wang YW; Gao P
    J Exp Clin Cancer Res; 2018 May; 37(1):100. PubMed ID: 29743122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.